A systematic review of 6 studies (88,190 participants) found that GLP-1 receptor agonists may reduce alcohol consumption and alcohol-related events, with dulaglutide showing a 29% greater likelihood of reducing intake, but RCT data on exenatide showed no significant effect overall.
29% more likely to reduce alcoholSecondary analysis of a dulaglutide RCT found participants taking the GLP-1 RA were 29% more likely to reduce their alcohol intake compared to placebo
What the researchers found
Exenatide RCT: no significant reduction in heavy drinking days vs placebo overall (95% CI -7.4 to 19.4, p=0.37), but fMRI showed reduced brain reward center cue reactivity in obese subgroup. Dulaglutide secondary analysis: 29% more likely to reduce alcohol intake (relative effect 0.71, CI 0.52-0.97, p=0.04). Observational studies showed fewer alcohol-related healthcare events with GLP-1 RAs.
Why it matters
Alcohol-related mortality is rising despite available treatments. The unexpected finding that diabetes/obesity drugs might reduce alcohol consumption has generated enormous public interest. This review provides the first comprehensive assessment of the clinical evidence, separating signal from hype.
The numbers in context
Searched multiple databases through August 2024. Included preclinical, observational, and clinical trial data.
How the study worked
Systematic review searching Ovid Medline, EMBASE, PsycINFO, ClinicalTrials.gov, and ProQuest through August 2024. Included 6 studies (88,190 total participants): 2 RCTs (286 participants) and 4 observational studies. Registered with PROSPERO. Assessed alcohol consumption changes, alcohol-related events, healthcare utilization, and fMRI cue reactivity.
Who was studied
Preclinical models and human studies examining GLP-1 drug use and alcohol consumption
What this study cannot tell us
Only 286 participants in RCTs — the vast majority (87,904) were from observational studies with inherent confounding. The exenatide RCT was not powered for alcohol as a primary outcome. Heterogeneous study designs, populations, and GLP-1 RA types make synthesis difficult. Publication bias possible in this high-interest area.
How to read the evidence
Rated preliminary: despite 88,190 participants, only 286 were in RCTs and neither RCT was designed with alcohol as the primary outcome. Observational data is promising but prone to confounding.
When this study was published
Published in 2024 with searches through August 2024. Captures the current state of evidence in this rapidly evolving field.
The bigger picture
The possibility that GLP-1 peptide drugs could treat addiction represents a paradigm shift. If confirmed, it would suggest that the reward pathways modulated by GLP-1 receptors extend far beyond appetite — potentially addressing substance use disorders with an entirely new drug class. However, this review shows we're still far from definitive evidence.
Questions still open
- Does the anti-alcohol effect vary between different GLP-1 RAs (semaglutide vs dulaglutide vs exenatide)?
- Is the mechanism primarily through reduced reward signaling, weight loss, or another pathway?
- Will the large ongoing RCTs of semaglutide for alcohol use disorder provide definitive answers?
Common questions
Can Ozempic or similar drugs help people drink less?
Why might a diabetes drug affect alcohol consumption?
Read the original research
Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review.
EClinicalMedicine, 78, 102920
Citation
Subhani, Mohsan; Dhanda, Ashwin; King, James A; Warren, Fiona C; Creanor, Siobhan; Davies, Melanie J; Eldeghaidy, Sally; Bawden, Stephen; Gowland, Penny A; Bataller, Ramon; Greenwood, Justin; Kaar, Stephen; Bhala, Neeraj; Aithal, Guruprasad P. (2024). Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review.. EClinicalMedicine, 78, 102920. https://doi.org/10.1016/j.eclinm.2024.102920